Hostname: page-component-7479d7b7d-767nl Total loading time: 0 Render date: 2024-07-12T00:07:42.295Z Has data issue: false hasContentIssue false

P0327 - Efficacy of Quetiapine monotherapy in rapid cycling bipolar disorder compared to Sodium Valproate: A pilot study

Published online by Cambridge University Press:  16 April 2020

T. Drieling
Affiliation:
Department of Psychiatry, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
J.M. Langosch
Affiliation:
Department of Psychiatry, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
N.C. Biedermann
Affiliation:
Department of Psychiatry, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
C. Born
Affiliation:
Department of Psychiatry, Ludwig-Maximilians-University of Munich, Munich, Germany
J. Sasse
Affiliation:
Department of Psychiatry, Carl-Gustav-Carus-University of Dresden, Dresden, Germany
H. Bauer
Affiliation:
AstraZeneca GmbH, Wedel, Germany
J. Walden
Affiliation:
Department of Psychiatry, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
M. Bauer
Affiliation:
Department of Psychiatry, Carl-Gustav-Carus-University of Dresden, Dresden, Germany
M. Berger
Affiliation:
Department of Psychiatry, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
H. Grunze
Affiliation:
Department of Psychiatry, Ludwig-Maximilians-University of Munich, Munich, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The aim of this study was to examine the long-term efficacy and safety of a monotherapy with quetiapine or sodium valproate (VPA) in patients with rapid cycling bipolar disorder.

This open-label trial was conducted at three German centers. A sample of 38 remitted or partly remitted bipolar patients with rapid cycling (quetiapine n = 22; VPA n = 16) were treated with quetiapine or VPA (flexible-dose design) up to 12 months. Analyses were based on the ITT-LOCF principle.

41 % of the patients with quetiapine and 50 % with VPA completed the trial. According to the Clinical Global Impression Scale responder rates tended to be higher for quetiapine than for VPA: i.e. 43 % vs. 25 % (depression), 48 % vs. 36 % (mania), and 43 % vs. 19 % (improvement in both mania and depression). There were no differences found between the treatment groups evaluating the HRSD, MADRS and YMRS. In contrast, Life Chart Method data showed that patients being treated with quetiapine had significantly less depressive days than patients on VPA whilst they did not differ in the number of days with manic symptoms. The incidence of adverse events, especially of orthostatic dysregulation and sedation was higher in the quetiapine group.

Quetiapine may be more effective than VPA regarding depressive symptoms and as effective as VPA in the treatment of manic symptoms in the long-term treatment of rapid cycling bipolar disorder. The side effect profile of quetiapine tends to be less favorable than the one of VPA.

Type
Poster Session II: Lithium And Other Mood Stabilisers
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.